Anti-BCMA CAR-T is named as a drug or biological intervention in 5 clinical trials in our China trial register, 2 of which are recruiting. The lead sponsor is Institute of Hematology & Blood Diseases Hospital, China. Registered phase: Phase 2. Conditions studied include Multiple Myeloma; Plasma Cell Leukemia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06793449 | BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma (ClinicalTrials.gov ↗) Multiple Myeloma |
Phase 2 | Recruiting |
| NCT06880393 | BCMA CAR-T for Dynamic High-risk Multiple Myeloma (ClinicalTrials.gov ↗) Multiple Myeloma |
Phase 2 | Recruiting |
| NCT05850286 | A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities (ClinicalTrials.gov ↗) Multiple Myeloma |
Phase 2 | Active, closed |
| NCT05860036 | A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma (ClinicalTrials.gov ↗) Multiple Myeloma |
Phase 2 | Active, closed |
| NCT05870917 | A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia (ClinicalTrials.gov ↗) Plasma Cell Leukemia |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Multiple Myeloma | 4 |
| Plasma Cell Leukemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 5 |
| Register | Anti-BCMA CAR-T trials |
|---|---|
| Clinical trials in China | 5 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anti-BCMA CAR-T works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anti-BCMA CAR-T (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.